Solithera’s Prospects Look Grim Following Complete Response Letter
Executive Summary
Even if Cempra has the funds to conduct another trial, there is no guarantee for approval; if approved, solithromycin’s labeling would likely limit use of the community-acquired pneumonia antibiotic.
You may also be interested in...
Cempra Gets Easier Path To CRL Response, But Who Will Fund The Study?
The biotech now only needs to investigate liver toxicity in 6,000 patients – down from 9,000 – to refile its NDA, but Cempra made clear that it won't initiate the study without an external funding source.
Deal Watch: Troubled Antibiotics Maker Cempra Exploring Strategic Options
North Carolina biotech may need to conduct a 9,000-patient safety study after solithromycin was rejected by FDA, but it has $231m in cash and another Phase III candidate. Apricus is clearing financial room by transferring ex-US rights to Vivaros to Ferring, while Heat is acquiring former spinout Pelican.
Cempra's Solithera Draws FDA Complete Response Letter On Liver Risks
Limited population approval pathway in 21st Century Cures law may not help Cempra overcome US agency's request for new 9,000-patient safety study of the macrolide antibiotic.